[Clinical efficacies of antifungal injections].
The incidence of fungal infection is increasing. Amphotericin B has been the gold standard in antifungal chemotherapy for a long time. Within the past few years, three novel antifungal agents have been approved to evaluate the clinical benefits in Japan. Liposomal amphotericin B is developed to reduce toxicities of amphotericin B. Voriconazole, a kind of the new broad-spectrum triazoles, is recommended for the primary treatment of invasive aspergillosis. Micafungin is a new lipopeptide antifungal agent of the echinocandin class. These drugs might provide an individualized and more effective antifungal therapy for each patient. On the other hand, we need to establish a new standard therapy.
Fujii
Yumi
Y
Department of Integrated Pulmonology, Tokyo Medical and Dental University.
Inase
Naohiko
N
Yoshizawa
Yasuyuki
Y
D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D054714:Echinocandins / Q000008:administration & dosage; D015725:Fluconazole / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007262:Infusions, Intravenous; D007267:Injections; D017964:Itraconazole / Q000008:administration & dosage; D055666:Lipopeptides / Q000008:administration & dosage; D008081:Liposomes; D000077551:Micafungin; D009181:Mycoses / Q000188:drug therapy*; D010755:Organophosphates / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008081:Liposomes; D010755:Organophosphates; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; C486878:fosfluconazole; D000666:Amphotericin B; D015725:Fluconazole; D065819:Voriconazole; D000077551:Micafungin